MindWalk Holdings Corp. HYFT

MindWalk Holdings pivots to ReefIQ, a data platform, with Q1 FY27 revenue of C$3.8m, up 21.3% YoY; gross profit C$2.2m, up 47.1%, lifting gross margin to 58.6% from 48.3%. ReefIQ deployment uses AMD Instinct GPUs via AMD and Vultr to expand compute capacity and cut onboarding costs for enterprise clients. About 80% of its commercial pipeline by value now comprises partnership-structured engagements rather than discrete projects, and ReefIQ rollout boosted sales and marketing spend. Operating cash burn eased to C$4.0m from C$4.2m. MindWalk secured a binding US$30m senior unsecured revolver at 7.00%, with no warrants or covenants; definitive agreement pending. Profitability remains pressured: operating losses rose 47% YoY to C$6.13m; net continuing ops loss $6.1m ($0.13/share); adjusted EBITDA negative $5.1m. The pivot toward platform-based revenue aims to scale ReefIQ without dilution, but execution risk and ongoing losses persist. ReefIQ pivot could materially alter revenue mix and enable non-dilutive financing, but ongoing losses limit upside.

MindWalk Holdings Corp. announced a production deployment of the OpenFold3 structure prediction model using AMD Inference Microservices on Vultr Kubernetes Engine, powered by AMD Instinct MI325X GPUs. The test, conducted with AMD and Vultr, validated AIM in a life-sciences workflow and achieved antibody-antigen inference roughly five times faster than MindWalk's prior environment. The end-to-end setup ran preprocessing, multiple sequence alignment, and GPU-accelerated inference within MindWalk’s ReefIQ discovery framework, enabling faster onboarding of enterprise partners. The deployment expands ReefIQ’s compute capacity and provides a standardized Kubernetes-native path from open-model to production, with findings shared for further platform work. MindWalk emphasizes a model-agnostic architecture and notes OpenFold3 is open-source, aiming to reduce time-to-first-result and cost per partner in regulated settings. Demonstrates a production-ready, open-model deployment path that could meaningfully accelerate enterprise onboarding and cost efficiency under ReefIQ.

MindWalk Holdings Corp. (HYFT) held its Q1 2027 earnings call, covering quarterly financial results, operations, and outlook. Earnings call releases key financial metrics and guidance that can materially move stock price and investor views.

MindWalk Holdings Corp. (HYFT) released its Q1 2027 earnings call summary covering quarterly financial results and business updates. Earnings call summaries deliver key financial results and guidance that typically drive notable shifts in investor sentiment and stock valuation.

MindWalk Holdings Corp (HYFT) reported 21% revenue growth in Q1 2027, driven by ReefIQ. 21% revenue growth points to noticeable effects on financial performance and market positioning for MindWalk Holdings Corp.

MindWalk Holdings Corp. achieved 21% revenue growth with gross margins expanding to 59% for fiscal first quarter 2027. Revenue growth combined with margin expansion signals stronger financial performance that can materially shift investor sentiment and company trajectory.

MindWalk Holdings Corp. secured a binding commitment for a US$30 million unsecured credit facility to fund biologics programs and commercial expansion. US$30 million credit facility supplies major funding to advance biologics programs and drive commercial growth for MindWalk Holdings Corp.

MindWalk Holdings Corp. (HYFT) posted a Q1 loss and missed revenue estimates. Q1 loss and revenue miss signal weaker results likely to weigh on near-term stock price and investor views.

MindWalk Holdings Corp. (HYFT) released Q1 earnings call highlights covering financial results, operational updates, and forward outlook. Quarterly earnings data typically affects near-term sentiment without altering long-term fundamentals.

MindWalk Holdings Corp. (HYFT) presented at a major computing event, highlighting AI's role in advancing drug discovery. Stage appearance at a top computing event signals major visibility gains and strategic positioning in AI drug discovery.

MindWalk Holdings Corp. presented ReefIQ™ for AI drug discovery at the AMD Advancing AI event. Showcase of ReefIQ at AMD event signals product visibility in AI drug discovery without confirmed contracts or revenue impact.

MindWalk Holdings Corp. (HYFT) issued a summary of its Q4 2026 earnings call. Earnings call summaries deliver financial results and outlook that moderately sway near-term stock performance and sentiment.

MindWalk Holdings Corp (HYFT) posted strong revenue growth in Q4 2026. Strong Q4 revenue growth supports better financial results and investor views but remains one of several ongoing factors.

MindWalk Holdings Corp. reports fiscal 2026 revenue rose 46% after completing its pivot to bio-native AI infrastructure. 46% revenue growth plus completed pivot to bio-native AI infrastructure marks major strategic advancement with strong potential to reshape company trajectory.

MindWalk Holdings Corp. (HYFT) joined the Russell 3000E as AI transforms drug discovery and will report earnings July 22. Russell 3000E inclusion may draw passive fund flows and earnings date sets a near-term catalyst.

MindWalk Holdings Corp. (NASDAQ: HYFT) added to the Russell 3000E Index, expanding institutional investment opportunity. Index inclusion can draw passive fund inflows and lift near-term demand without changing operations or fundamentals.

MindWalk Holdings Corp. (HYFT) files patent for high-dimensional biological data architecture powering AI drug discovery. Patent filing advances core AI drug discovery technology and IP position.

MindWalk Holdings Corp. (NASDAQ: HYFT) launches ReefIQ™, a biological context layer for AI drug discovery. ReefIQ™ launch introduces major AI technology for drug discovery with potential to significantly shift company trajectory.

MindWalk Holdings Corp. (HYFT) preclinical dengue data confirmed HYFT® computational predictions. Immunogens designed on the predicted target produced cross-reactive antibodies against antigens of all four dengue serotypes. Results were reproduced across two independent campaigns. Positive preclinical validation of dengue immunogens supports product innovation yet remains early-stage with limited near-term financial or market impact.

MindWalk Holdings Corp. prioritizes biological principles as the core driver for its strategic initiatives and product development. Emphasis on foundational biology may moderately influence long-term innovation and positioning but lacks details on immediate financial or market shifts.

MindWalk Holdings Corp (HYFT) reported a significant revenue surge and announced key strategic shifts during its Q3 2026 earnings call. Revenue surge boosts financial performance while strategic shifts indicate major trajectory changes for HYFT.

MindWalk Holdings Corp. (HYFT) Q3 2026 earnings call transcript covers quarterly financial results, management discussions, strategic updates, and forward guidance. Q3 2026 earnings transcript discloses financial performance, strategic initiatives, and outlook that could significantly sway HYFT's market trajectory and investor sentiment.

MindWalk Holdings Corp. (HYFT) reports Q3 fiscal 2026 financial results. Quarterly financial results reporting typically triggers significant market reactions and influences future performance expectations for HYFT.

MindWalk Holdings Corp. (HYFT) Q3 2026 earnings call summary covers quarterly financial results, operational updates, and forward guidance. Quarterly earnings summary provides insights into financial health and outlook with moderate influence on market performance.

MindWalk Holdings Corp. (HYFT) reported a Q3 loss and revenue below analyst estimates. Q3 loss and missed revenue estimates highlight weak financial performance with moderate potential to affect short-term market sentiment and stock price.

MindWalk Holdings Corp. (HYFT) announces B Cell Llama™, a nanobody discovery platform designed for bispecific antibodies and cell therapies. Launching B Cell Llama™ introduces a specialized nanobody platform targeting high-growth bispecific and cell therapy markets, likely enhancing HYFT's innovation pipeline and investor appeal.

MindWalk Holdings Corp. has applied its HYFT® technology to identify functional adjacency related to portfolio risk in AI-designed therapeutics. This innovative approach aims to enhance the understanding of risk factors associated with therapeutic development, potentially improving decision-making processes in the field. The application of HYFT® technology in AI-designed therapeutics could significantly influence the company's strategic direction and market positioning.

MindWalk Holdings Corp. (HYFT) has made a significant breakthrough in targeting pathogenic TDP-43, a protein associated with neurodegenerative diseases. This discovery validates the precision of MindWalk's platform and positions the company as a key player in the development of therapies for conditions like ALS and frontotemporal dementia. The advancement is expected to enhance MindWalk's research capabilities and attract potential partnerships in the biotech sector. The breakthrough discovery could significantly alter MindWalk's trajectory and investor sentiment by enhancing its competitive position in the neurodegenerative disease market.

MindWalk Holdings Corp. (HYFT) has made significant advancements in its Universal Influenza Program, achieving a breakthrough functional insight that could enhance the development of effective influenza treatments. This progress positions the company favorably within the competitive landscape of healthcare innovation, potentially leading to improved market opportunities and partnerships. The breakthrough in the Universal Influenza Program is likely to significantly impact MindWalk's future performance and market positioning.

MindWalk Holdings Corp. (HYFT) has made significant progress in its Universal Influenza Program, achieving a breakthrough functional insight that could enhance the development of effective influenza treatments. This advancement positions the company favorably in the competitive landscape of healthcare innovation, particularly in addressing influenza-related challenges. The breakthrough in the Universal Influenza Program is likely to significantly impact MindWalk's future performance and market positioning.